Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 2, 2014

Voyager Licenses ReGenX' NAV Vectors to Develop CNS Disease Gene Therapies

  • Voyager Therapeutics has entered a license agreement with ReGenX to use the gene therapy firm's NAV® vectors to develop and commercialize gene therapies to treat amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, and Huntington's disease. The license ReGenX granted Voyager per the agreement is nonexclusive and worldwide; Voyager is also picking up sublicensing rights to the NAV vectors.

    ReGenX is getting an undisclosed upfront fee from Voyager in exchange, plus ongoing fees, milestones, and sales royalties of products incorporating the vectors. ReGenX is also getting a share of the sublicensing revenues. Voyager's interim CEO Mark Levin added in a statement that the company believes the rights to use the NAV vectors will position it to advance more quickly the development of breakthrough CNS gene therapies.

    ReGenX' NAV vector technology includes the AAV vectors rAAV7, rAAV8, rAAV9, and rAAVrh10, and Voyager isn't the only organization who've expressed an interest in them: This past March ReGenX gave Laboratorios Dr. Esteve a nonexclusive worldwide license to use its NAV rAAV9 vectors to develop treatments of the rare lysosomal storage disease mucopolysaccharidosis type IIIA (a.k.a, Sanfilippo syndrome Type A) in humans.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »